|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systematic review of nutrition screening and assessment in inflammatory bowel disease显示文摘BACKGROUND Malnutrition is prevalent in inflammatory bowel disease (IBD). Multiple nutrition screening (NST) and assessment tools (NAT) have been developed for general populations, but the evidence in patients with IBD remains unclear. AIM To systematically review the prevalence of abnormalities on NSTs and NATs, whether NSTs are associated with NATs, and whether they predict clinical outcomes in patients with IBD. METHODS Comprehensive searches performed in Medline, CINAHL Plus and PubMed. Included: English language studies correlating NSTs with NATs or NSTs/NATs with clinical outcomes in IBD. Excluded: Review articles/case studies;use of body mass index/laboratory values as sole NST/NAT;age<16. RESULTS Of 16 studies and 1618 patients were included, 72% Crohn’s disease and 28% ulcerative colitis. Four NSTs (the Malnutrition Universal Screening Tool, Malnutrition Inflammation Risk Tool (MIRT), Saskatchewan Inflammatory Bowel Disease Nutrition Risk Tool (SaskIBD-NRT) and Nutrition Risk Screening 2002 (NRS-2002) were significantly associated with nutritional assessment measures of sarcopenia and the Subjective Global Assessment (SGA). Three NSTs (MIRT, NRS-2002 and Nutritional Risk Index) were associated with clinical outcomes including hospitalizations, need for surgery, disease flares, and length of stay (LOS). Sarcopenia was the most commonly evaluated NAT associated with outcomes including the need for surgery and post-operative complications. The SGA was not associated with clinical outcomes aside from LOS. CONCLUSION There is limited evidence correlating NSTs, NATs and clinical outcomes in IBD. Although studies support the association of NSTs/NATs with relevant outcomes, the heterogeneity calls for further studies before an optimal tool can be recommended. The NRS-2002, measures of sarcopenia and developments of novel NSTs/NATs, such as the MIRT, represent key, clinically-relevant areas for future exploration. | Suqing Li Michael Ney Tannaz Eslamparast Ben Vandermeer Kathleen P Ismond Karen Kroeker Brendan Halloran Maitreyi Raman Puneeta Tandon | 2019 | World Journal of Gastroenterology2019，25，28： | 9 |
| 2 | Novel biomarkers for patient stratification in colorectal cancer:A review of definitions,emerging concepts,and data显示文摘Colorectal cancer(CRC) treatment has become more personalised,incorporating a combination of the individual patient risk assessment,gene testing,and chemotherapy with surgery for optimal care.The improvement of staging with high-resolution imaging has allowed more selective treatments,optimising survival outcomes.The next step is to identify biomarkers that can inform clinicians of expected prognosis and offer the most beneficial treatment,while reducing unnecessary morbidity for the patient.The search for biomarkers in CRC has been of significant interest,with questions remaining on their impact and applicability.The study of biomarkers can be broadly divided into metabolic,molecular,micro RNA,epithelial-to-mesenchymal-transition(EMT),and imaging classes.Although numerous molecules have claimed to impact prognosis and treatment,their clinical application has been limited.Furthermore,routine testing of prognostic markers with no demonstrable influence on response to treatment is a questionable practice,as it increases cost and can adversely affect expectations of treatment.In this review we focus on recent developments and emerging biomarkers with potential utility for clinical translation in CRC.We examine and critically appraise novel imaging and molecular-based approaches; evaluate the promising array of micro RNAs,analyze metabolic profiles,and highlight key findings for biomarker potential in the EMT pathway. | Manish Chand Deborah S Keller Reza Mirnezami Marc Bullock Aneel Bhangu Brendan Moran Paris P Tekkis Gina Brown Alex Mirnezami Mariana Berho | 2018 | World Journal of Gastrointestinal Oncology2018，10，7： | 2 |
| 3 | Fate of heavy metals and radioactive metals in gasification of sewage sludge 显示文摘 | Thomas W Marrero Brendan P | 2004 | Waste Management2004，24，： | 1 |
| 4 | Transient encephalopathy in a postoperative nomalcoholicfemale with Marchiafava-Bignami dis- ease 显示文摘 | Lesli E Brendan P KatieD | 2007 | Clinical Neurology and Neurosurgery2007，109，： | 1 |
| 5 | Reduced PWM harmonic distortion for multilevel inverters operating over a wide modulation range显示文摘 | Brendan P M Donald G H Thierry M | 2006 | IEEE Transactions on Power Electronics2006，21，4： | 1 |
| 6 | Line scan diffusion tensor MRI of the cervical spinal cord in preterm infants显示文摘 | Brendan P Murphy MB Gary BC | 2001 | J Magn Reson Imaging2001，13，6： | 1 |
| 7 | ZapA,a virulence factor in a rat model of Proteus mirabilis induced acute and chronic prostatitis显示文摘 | Van P Robert B Brendan F G | 2008 | Infect Immun2008，11，： | 1 |
| 8 | External eating, impulsivity and attentional bias to food cues 显示文摘 | Ruihua H Karin M Brendan P | 2011 | Appetite2011，56，2： | 1 |
| 9 | Fate of heavy metals and radioactive mentals in gasification of sewage sludge显示文摘 | Thomas W Marrero Brendan P McAuley William R Sutter- lin | 2004 | Waste Management2004，24，： | 1 |
| 10 | Human inhibitor of apoptosis proteins:why xiap is the black sheep of the family显示文摘 | Brendan P Eckelman Guy S Salvesen Fiona L Scott | | 0，，： | 1 |
| 11 | heman inhibitor of apoptosis proteins:why xiap is the black sheep of the family 显示文摘 | Brendan p eckelman guy s | 2006 | EMBO reports2006，7，： | 1 |
| 12 | A meta-analyis of prehospieal care times for trauma显示文摘 | Brendan G C Joel M C John P P | 2006 | Prehospical emargency core2006，10，： | 1 |
| 13 | Monocyte count,but not C-reactive protein or interleukin-6,is an independent risk marker for subclinical carotid atherosclerosis显示文摘 | Caroline ML John P Brendan M | 2004 | Stroke2004，35，7： | 1 |
| 14 | Compressive Rheology of Ag- gregated Particulate Suspensions 显示文摘 | BRENDAN G SHANE P PETER J S | 2006 | Korea-Australia Rheology Jour- nal2006，18，4： | 1 |
| 15 | Rhodium(Ⅱ)-catalyzed cross-coupling of diazo compounds显示文摘 | Jorn H H Brendan T P Philip P | 2011 | Angew Chem Int Ed2011，50，11： | 1 |
| 16 | A First Assessment of Lichen Diversity for One of North Americas's ' Biodiversity Hotspots' in the Southern Appalachians of Virginia显示文摘 | HODKINSON BRENDAN P | 2010 | Castanea2010，75，1： | 1 |
| 17 | Opportunities for harmonic cancellation with carrier-based pwm for two-level and multilevelcascaded inverters显示文摘 | HOLMES D G BRENDAN P | 2001 | IEEE Transactions on Industry Appilcations2001，37，2： | 1 |
| 18 | ZapA,A Virulence Factor in a Rat Model of Proteus Mirabilis-Induced Acute and Chronic Prostatitis显示文摘 | VAN P ROBERT B BRENDAN F G | | 0，，11： | 1 |
| 19 | Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders显示文摘Immunosuppressive agents, such as thiopurines, methotrexate, and biologics, have revolutionized the treatment of inflammatory bowel disease(IBD). However, a number of case reports, case control studies and retrospective studies over the last decade have identified a concerning link between immunosuppression and lymphoproliferative disorders(LPDs), the oncological phenomenon whereby lymphocytes divide uncontrollably. These LPDs have been associated with Epstein-Barr virus(EBV) infection in which the virus provides the impetus for malignant transformation while immunosuppression hampers the immune system's ability to detect and clear these malignant cells. As such, the use of immunosuppressive agents may come at the cost of increased risk of developing LPD. While little is known about the LPD risk in IBD, more is known about immunosuppression in the post-transplantation setting and the development of EBV associated posttransplantation lymphoproliferative disorders(PTLD). In review of the PTLD literature, evidence is available to demonstrate that certain immune suppressants such as cyclosporine and T-lymphocyte modulators in particular are associated with an increased risk of PTLD development. As well, high doses of immunosuppressive agents and multiple immunosuppressive agent use are also linked to increased PTLD development. Here,we discuss these findings in context of IBD and what future studies can be taken to understand and reduce the risk of EBV-associated LPD development from immunosuppression use in IBD. | Grace Y Lam Brendan P Halloran Anthea C Peters Richard N Fedorak | 2015 | World Journal of Gastrointestinal Pathophysiology2015，6，4： | 1 |
| 20 | Opportunities for harmonic cancellation with carrier-based PWM for two-level and multilevel cascaded inverters显示文摘 | Donald Grahame Holmes Brendan P McGrath | 2001 | IEEE Transactions on Industry Applications2001，37，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员